Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel

Manabu Seino, Tsuyoshi Ohta, Akiko Sugiyama, Hirotsugu Sakaki, Takeshi Sudo, Seiji Tsutsumi, Shogo Shigeta, Hideki Tokunaga, Masafumi Toyoshima, Nobuo Yaegashi, Satoru Nagase

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


Introduction: Uterine serous carcinoma (USC) is more aggressive than other subtypes of endometrial carcinoma and is associated with a poor prognosis. We analyzed the metabolomic profile of USC with acquired resistance to paclitaxel. Results: Glutathione (GSH) concentration in PTX-1 cells was higher than in USPC- 1 cells. In addition, GSH concentration in the USPC-1 cells increased after treatment with paclitaxel but was unchanged in PTX-1 cells. Glucose-6-phosphate (G6P) and ribose-5-phosphate (R5P) concentrations in PTX-1 cells were higher than those in USPC-1 cells. G6P concentration in the USPC-1 cells was unchanged after treatment with paclitaxel, while it decreased in PTX-1 cells. Conclusion: Our results indicate that increased GSH and glucose metabolism may be related to acquiring resistance to paclitaxel in USC and thus may be targets for anti-USC therapy. Materials and Methods: We compared metabolic profiles and reactions to paclitaxel in both a wild type USC cell line (USPC-1) and PTX-1, a cell line derived from USPC-1 which acquired paclitaxel resistance, using a capillary electrophoresis CE-MS/MS system.

Original languageEnglish
Pages (from-to)31985-31998
Number of pages14
Issue number62
Publication statusPublished - 2018 Aug 10


  • Endometrial cancer
  • Metabolomic analysis
  • Paclitaxel
  • Uterine serous carcinoma


Dive into the research topics of 'Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel'. Together they form a unique fingerprint.

Cite this